Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
Abstract
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models. RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1–77.0 mg/dL), those with Lp(a) level >50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06–1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46–2.48]). CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.
Article Details
Authors (13)
Harpreet S. Bhatia
Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla.
Simon Wandel
Novartis Pharma AG, Basel, Switzerland (S.W., A.L., K.B.).
Peter Willeit
Anastasia Lesogor
Novartis Pharma AG, Basel, Switzerland (A.S., A.L.).
Keith Bailey
Paul M. Ridker
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (P.M.R.).
Paul Nestel
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (P.N.).
John Simes
NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia (J.S.).
Andrew Tonkin
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (A.T.).
Gregory G. Schwartz
Cardiology Section, Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, CO (G.G.S.).
Helen Colhoun
MRC Human Genetics Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (H.C.).
Christoph Wanner
Sotirios Tsimikas